MannKind Corp. on Monday announced that Steven Binder has joined the company as chief financial officer.
The Valencia biotech said Binder will assume the responsibilities of Rose Alinaya – who previously served as acting chief financial officer – in finance, accounting and investor relations. Binder is the third executive appointment at MannKind in the recent months; the company selected Chief Executive Michael Castagna and Chief Commercial Officer Patrick McCauley less than a week ago.
Before joining MannKind, Binder was chief financial officer for international arm of Stryker Corp., a Michigan medical device company. He has 25 years of experience in the health care industry.
“We are very excited to have Steve join MannKind and our executive leadership team. His deep experience in finance and his commercial acumen acquired through a variety of senior leadership roles in multi-national health care companies will be a clear competitive advantage for us,” Castagna said in a statement. “Steve joins MannKind at an exciting period as we develop into a world class biopharmaceutical company.”
MannKind’s sole commercial product is Afrezza, an inhalable insulin.
Shares of MannKind (MNKD) Monday closed up 7 cents, or 5 percent, to $1.35 on the Nasdaq.